ClinicalTrials.gg
CompletedNCT07698288ACL25-PC007Updated Jul 13, 2026

Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed Conditions

An interventional study of Tamsulosin 0.4 mg ER tablet and Tamsulosin 0.4 mg ER tablet in Bioequivalence, sponsored by ADIUM. Completed at 1 site in Mexico. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by ADIUM · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2026, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x4, replicated, two treatments, four periods, two sequences controlled clinical study

Read the detailed description

The study design was a randomized, open-label, two-way, crossover, single-dose, prospective, and longitudinal study, with a 7-day wash-out period before next dosing; to compare the pharmacokinetic profile (Cmax, AUC0-t and AUC0-inf) of two 0.4 mg tamsulosin extended release tablet in sixty-six (66) healthy male Mexican adult volunteers aged 18 to 55 years.

02

Conditions studied

  • Bioequivalence

Keywords

  • tamsulosin
  • pharmacokinetics
  • bioequivalence
03

In context

Lead sponsor

ADIUM is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

"Inclusion Criteria:

  1. Age between 18 and 55 years.
  2. Clinically healthy male according to the updated medical history prior to the start of the study.
  3. Not blocked in the COFEPRIS research subject database.
  4. between 18 and 27 kg/m².
  5. Normal vital signs: Heart rate between 60 and 99 beats per minute, respiratory rate between 12 and 20 breaths per minute, systolic blood pressure between 90-130 mmHg, diastolic blood pressure between 60-89 mmHg, and temperature between 36.0 and 37.4°C.
  6. (ECG) without any signs of pathology.
  7. Clinical laboratory test results within normal limits or with clinically insignificant variations.
  8. Negative biosafety tests for the presence of (HIV), virus (HBV), virus (HCV), and varicella-zoster virus (VDRL).
  9. Negative drug screening tests for amphetamines, benzodiazepines, cocaine, methamphetamines, morphine, and tetrahydrocannabinol (THC).
  10. Negative breath alcohol test.
  11. Research subjects with no history of alcohol abuse or dependence, psychoactive substance abuse, or chronic medication use.
  12. Subjects with a signed form.

Exclusion Criteria:

  1. Subjects with a history of to the study drug.
  2. Subjects with lactose intolerance.
  3. Subjects with a history of cardiovascular, renal, hepatic, metabolic, gastrointestinal, neurological, endocrine, hematopoietic (any type of anemia), mental illness, or other organic abnormalities that could affect the pharmacokinetic study of the study product.
  4. Subjects requiring any medication during the course of the study that interferes with the quantification or pharmacokinetics of the study drug.
  5. Subjects who have been exposed to agents known to induce or inhibit hepatic enzyme systems or who have taken potentially toxic medications within 30 days prior to the start of the study.
  6. Subjects who, prior to receiving the study drug, have taken medications such as those described in section 3.11 "Drug Interactions."
  7. Subjects who have been hospitalized for any reason within sixty days prior to the start of the study or who have been seriously ill within thirty days prior to the start of the study.
  8. Subjects who have received an drug within ninety days prior to the start of the study.
  9. Subjects who have donated or lost 450 mL or more of blood within sixty days prior to the start of the study.
  10. Research subjects with a history of alcohol or psychoactive substance abuse or dependence, or chronic medication use.
  11. Subjects who have consumed beverages or foods containing xanthines (coffee, tea, cocoa, chocolate, yerba mate, cola, etc.) or have consumed charcoal-grilled foods within 12 hours prior to administration of the medication dose.
  12. Subjects who have consumed grapefruit, cranberry, or pomegranate juice within 12 hours prior to the study.
  13. Subjects who have smoked at least 12 hours before the start of the study.
  14. Subjects who have ingested alcoholic beverages 48 hours prior to administration of the dose."
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Reference

    Omnic Ocas, 0.4 mg, ER tablet, Reference

    Drug: Tamsulosin 0.4 mg ER tablet

  • Experimental
    Test

    Tamsulosin 0.4 mg ER tablet, test

    Drug: Tamsulosin 0.4 mg ER tablet

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on the pharmacokinetic parameter: Cmax

    Bioequivalence based on the pharmacokinetic parameter: Cmax

    Time frame: Through 72 Hours Post Dose

  2. Bioequivalence based on the pharmacokinetic parameter: AUC0-t

    Bioequivalence based on the pharmacokinetic parameter: AUC0-t

    Time frame: Through 72 hours Post Dos

Secondary outcomes

  1. Characterize the pharmacokinetic parameter: AUC0-inf

    Characterize the pharmacokinetic parameter: AUC0-inf

    Time frame: Through 72 Hours Post Dose

  2. Characterize the pharmacokinetic parameter: time to maximum concentration (tmax)

    Characterize the pharmacokinetic parameter: time to maximum concentration (tmax)

    Time frame: Through 72 Hours Post Dose

  3. Characterize the pharmacokinetic parameter: elimination constant (Ke)

    Characterize the pharmacokinetic parameter: elimination constant (Ke)

    Time frame: Through 72 Hours Post Dose

  4. Characterize the pharmacokinetic parameter: half-life (t1/2)

    Characterize the pharmacokinetic parameter: half-life (t1/2)

    Time frame: Through 72 Hours Post Dose

  5. Establish the frequency, severity, and seriousness of adverse events that occurred during the study.

    Establish the frequency, severity, and seriousness of adverse events that occurred during the study.

    Time frame: Until the final visit (7 days after the last dose)

07

Study locations

1 site
  • Axis Clinicals Latina, S.A. de C.V.
    Mexico City, Mexico City 07870, Mexico
08

References and documents

Publications

  • Accennato VAC, Costa F, Riccio MF, Bernasconi G, Noboli AC. Bioequivalence Between Two Fixed Dose Combinations of Dutasteride and Tamsulosin in Male Subjects Under Fasting and Fed Conditions. Int Ann Med. 2017;1(10).

Individual participant data

Plan to share: Yes — Upon request, the clinical research site will provide this data with prior authorization from the sponsor, without disclosing personal information. All information will be uniquely identified by the research subject's initials and/or their assigned randomization number, thus guaranteeing their privacy.

Supporting information: Study protocol, Clinical study report

Time frame: Upon request

Access criteria: Upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Apr 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Feb 12, 2026
Primary completionActual
Apr 16, 2026
CompletionActual
Apr 16, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698288
Lead sponsor
ADIUM
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Feb 12, 2026
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion